Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.
SNT-5505 (amsulostat)'s own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for SNT-5505 (amsulostat). Showing past 6 months and next 12 months · 11 later hidden.
Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.
| Trial | Sponsor | Class | Phase / Line | Design | Primary endpoint | Dosing | Key eligibility | n |
|---|---|---|---|---|---|---|---|---|
| SNT-5505 (amsulostat) | Syntara | Kinase Inhibitor | Phase 1/2 | 0 | ||||
| A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia | Otsuka Australia Pharmaceutical Pty Ltd | Small Molecule Other |
Read-across commentary attached per trial. Phase ordering preserved within each group.
External analyst notes, journalism, and industry commentary cited with attribution.
"Sponsor guided" dates come from IR materials and earnings calls; hover for the cited source. "CT.gov proxy" dates fall back to the registry primary completion date — actual readouts typically follow by 3-6 months.
Phase 3 |
| — |
| — |
| — |
| — |
| — |
| AZA+Lus VS AZA Monotherapy in HR-MDS | Peking Union Medical College Hospital | Kinase Inhibitor | Phase 3 | — | — | — | — | — |
| Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT) | Gruppo Italiano Malattie EMatologiche dell'Adulto | Allogeneic Cell Therapy Other | Phase 3 | — | — | — | — | — |
| Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | AbbVie | Small Molecule Other | Phase 3 | — | — | — | — | — |
| Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4). | Ascentage Pharma Group Inc. | Other | Phase 3 | — | — | — | — | — |
| A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT | University of Birmingham | Other | PHASE2/PHASE3 | — | — | — | — | — |
| Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS | M.D. Anderson Cancer Center | Small Molecule Other | PHASE2/PHASE3 | — | — | — | — | — |
| Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia | National Cancer Institute (NCI) | Small Molecule Other | Phase 2 | — | — | — | — | — |
| Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia | City of Hope Medical Center | Small Molecule Other | Phase 2 | — | — | — | — | — |
| Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy | Masonic Cancer Center, University of Minnesota | Allogeneic Cell Therapy Other | Phase 2 | — | — | — | — | — |
| Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients | Stichting Hemato-Oncologie voor Volwassenen Nederland | Kinase Inhibitor | Phase 2 | — | — | — | — | — |
| Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPN | The First Affiliated Hospital with Nanjing Medical University | Kinase Inhibitor | Phase 2 | — | — | — | — | — |
| Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS | University of Virginia | Other | Phase 2 | — | — | — | — | — |
| Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy | GCP-Service International West GmbH | Small Molecule Other | Phase 2 | — | — | — | — | — |
| Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS | First Affiliated Hospital of Zhejiang University | Small Molecule Other | Phase 2 | — | — | — | — | — |
| Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients | Institute of Hematology & Blood Diseases Hospital, China | Small Molecule Other | Phase 2 | — | — | — | — | — |
| A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes | Akeso | Monoclonal antibody | Phase 2 | — | — | — | — | — |
| Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML | Ryvu Therapeutics SA | Kinase Inhibitor | Phase 2 | — | — | — | — | — |
| Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS | First Affiliated Hospital of Zhejiang University | Small Molecule Other | Phase 2 | — | — | — | — | — |
| CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | M.D. Anderson Cancer Center | Small Molecule Other | Phase 2 | — | — | — | — | — |
| VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS | Beijing 302 Hospital | Other | Phase 2 | — | — | — | — | — |
| Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant | M.D. Anderson Cancer Center | Other | Phase 2 | — | — | — | — | — |
| Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor | St. Petersburg State Pavlov Medical University | Small Molecule Other | Phase 2 | — | — | — | — | — |
| TMLI Plus Chemotherapy in High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | Other | Phase 2 | — | — | — | — | — |
| Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome | M.D. Anderson Cancer Center | Small Molecule Other | Phase 2 | — | — | — | — | — |
| Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) | National Cancer Institute (NCI) | Kinase Inhibitor | Phase 2 | — | — | — | — | — |
| Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) | National Cancer Institute (NCI) | Other | Phase 2 | — | — | — | — | — |
| HCT With PTCy in Higher-risk MDS | Asan Medical Center | Other | Phase 2 | — | — | — | — | — |
| UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia | Ciusss de L'Est de l'Île de Montréal | Allogeneic Cell Therapy Other | Phase 2 | — | — | — | — | — |
| Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation | University Hospital Tuebingen | Small Molecule Other | Phase 2 | — | — | — | — | — |
| A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm | M.D. Anderson Cancer Center | Kinase Inhibitor | Phase 2 | — | — | — | — | — |
| Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation in Very High-Risk MDS Patients Based on IPSS-M Stratification | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Other | Phase 2 | — | — | — | — | — |
| Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome | M.D. Anderson Cancer Center | Antibody-drug conjugate | Phase 2 | — | — | — | — | — |
| MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies | Masonic Cancer Center, University of Minnesota | Allogeneic Cell Therapy Other | Phase 2 | — | — | — | — | — |
| A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts | M.D. Anderson Cancer Center | Small Molecule Other | Phase 2 | — | — | — | — | — |
| Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) | M.D. Anderson Cancer Center | Small Molecule Other | Phase 2 | — | — | — | — | — |
| Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by Transplantation in Higher-Risk Myelodysplastic Syndrome Patients | Institute of Hematology & Blood Diseases Hospital, China | Other | Phase 2 | — | — | — | — | — |
| Ascorbate in Myelodysplastic Syndrome | Prajwal Dhakal | Small Molecule Other | Phase 2 | — | — | — | — | — |
| TMLI/Fludarabine/Melphalan Conditioning for Allogeneic Transplantation in High-risk Myelodysplastic Syndrome or Acute Myeloid Leukemia. | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | Other | Phase 2 | — | — | — | — | — |
| Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | M.D. Anderson Cancer Center | Small Molecule Other | Phase 2 | — | — | — | — | — |
| A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) | BioLite, Inc. | Small Molecule Other | Phase 2 | — | — | — | — | — |
| Clinical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Prior to Hematopoietic Stem Cell Transplantation in Patients With Higher-Risk Myelodysplastic Syndromes | Yehui Tan | Small Molecule Other | Phase 2 | — | — | — | — | — |
| Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS) | University of Illinois at Chicago | Surgical Device | Phase 2 | — | — | — | — | — |
| Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy) | National Cancer Institute (NCI) | Kinase Inhibitor | Phase 2 | — | — | — | — | — |
| Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia | M.D. Anderson Cancer Center | Small Molecule Other | Phase 2 | — | — | — | — | — |
| Venetoclax-containing Therapy Combined With Microtransplant for Intermediate-risk and Higher MDS | Beijing 302 Hospital | Small Molecule Other | Phase 2 | — | — | — | — | — |
| A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic Syndrome | Akeso | Monoclonal antibody | PHASE1/PHASE2 | — | — | — | — | — |
| Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS | University of Colorado, Denver | Small Molecule Other | PHASE1/PHASE2 | — | — | — | — | — |
| Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes | Groupe Francophone des Myelodysplasies | Small Molecule Other | PHASE1/PHASE2 | — | — | — | — | — |
| Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | M.D. Anderson Cancer Center | Small Molecule Other | PHASE1/PHASE2 | — | — | — | — | — |